Jonathan Meyer

Dr. Jonathan M. Meyer, a Voluntary Clinical Professor at UC San Diego and psychopharmacology expert, discusses the evolution of muscarinic-targeting treatments for schizophrenia. He highlights the historical shifts from dopamine-centric therapies to the promising role of muscarinic receptors. Key topics include the challenges and innovations in cognitive impairment management, new drugs like xanomeline-trospium, and the impact of neurotransmitter interactions. Meyer emphasizes tailored treatment approaches and the importance of individualized dosing strategies for enhancing patient outcomes.